SIRT1 and non-small cell lung carcinoma: Hypoxia-mediated inactivation of the SIRT1/AMPK pathway led to cisplatin and doxorubicin resistance, indicating that this may be a strategy to overcome hypoxia-induced chemoresistance in NSCLC (78).